Chapter 3: Pharmacodynamics — Module 6: Applied Clinical Pharmacodynamics — Drug Classes, Receptor Selectivity and Therapeutic Windows
1. A 58-year-old man with a history of myocardial infarction, preserved ejection fraction, and well-controlled asthma on low-dose inhaled corticosteroids is prescribed bisoprolol 2.5 mg daily for secondary prevention. At follow-up, his peak flow is mildly reduced from baseline but he has no dyspnea and his asthma is clinically stable. Which of the following best describes the appropriate pharmacodynamic interpretation and management?
A) Bisoprolol must be stopped immediately -- any reduction in peak flow confirms beta2-mediated bronchoconstriction, and continued use risks fatal bronchospasm regardless of dose or clinical symptoms
B) The peak flow reduction is unrelated to bisoprolol -- cardioselective beta-blockers at any dose produce zero beta2 receptor occupancy in the airways and cannot cause any bronchospasm or airflow limitation
C) Bisoprolol should be immediately replaced with carvedilol, which adds alpha1 blockade to its beta-blocking profile; alpha1 blockade in the airways reverses any beta2-mediated bronchoconstriction and protects against asthma exacerbation
D) Bisoprolol's cardioselectivity at 2.5 mg provides substantial beta1 preference with limited beta2 occupancy at this low dose -- the mild peak flow reduction likely reflects some degree of beta2 airway involvement consistent with the dose-dependent nature of cardioselectivity; the appropriate response is clinical assessment of symptom burden, spirometry if indicated, and consideration of dose reduction rather than immediate cessation, since the cardiovascular benefit of post-MI beta-blockade in this patient substantially outweighs the modest and clinically asymptomatic airway effect; if symptoms develop or airflow significantly worsens, dose reduction or discontinuation would be warranted
E) The appropriate response is to add a leukotriene receptor antagonist and double the bisoprolol dose -- higher doses of cardioselective agents paradoxically provide more airway protection through beta2 receptor downregulation
ANSWER: D
Rationale:
This case illustrates the nuanced clinical application of beta-blocker pharmacodynamics in a patient where two strong pharmacological considerations compete: the cardiovascular imperative for post-MI beta-blockade (which reduces recurrent MI, sudden cardiac death, and all-cause mortality) and the respiratory risk of any degree of airway beta2 blockade in an asthmatic patient. Bisoprolol has one of the highest beta1/beta2 selectivity ratios of any available beta-blocker (approximately 75-fold preference for beta1 over beta2), and at 2.5 mg daily -- a low dose -- the degree of beta2 occupancy in the airways is modest. The mild peak flow reduction without symptoms suggests that some airway beta2 involvement is occurring (consistent with dose-dependent loss of selectivity) but is not clinically significant at this stage. The appropriate pharmacodynamic response is proportionate -- assess symptom burden, consider spirometry, and monitor rather than reflexively stopping a medication with clear cardiovascular mortality benefit in a post-MI patient. Multiple clinical trials and meta-analyses have demonstrated that cardioselective beta-blockers in patients with mild-to-moderate asthma produce modest reductions in FEV1 (forced expiratory volume in one second) that are generally well-tolerated when the cardiovascular indication is compelling.
Option A: Option A is incorrect -- immediate cessation of a drug providing post-MI secondary prevention based on asymptomatic peak flow reduction is clinically disproportionate; the decision must weigh benefit and risk.
Option B: Option B is incorrect -- cardioselective agents have relative (not absolute) selectivity; at any dose some beta2 occupancy occurs, explaining the observed peak flow reduction.
Option C: Option C is incorrect -- carvedilol is non-selective (blocks beta1, beta2, and alpha1); switching from a cardioselective to a non-selective agent in an asthmatic patient would worsen beta2 blockade; alpha1 blockade does not reverse beta2-mediated bronchoconstriction.
Option E: Option E is incorrect -- increasing bisoprolol dose at higher concentrations produces more beta2 blockade, not less; there is no paradoxical airway protective effect of higher doses.
2. A 34-year-old woman with bipolar I disorder on lithium 900 mg daily has maintained a therapeutic serum level of 0.8 mmol/L for two years. She develops knee pain and self-medicates with ibuprofen 400 mg three times daily for one week. She presents to the emergency department with nausea, tremor, ataxia, and confusion. Her lithium level is 1.9 mmol/L. Which of the following best explains the pharmacodynamic and pharmacokinetic mechanism of this interaction?
A) Ibuprofen is a CYP2D6 inhibitor that reduces hepatic lithium metabolism, raising plasma levels by reducing first-pass clearance of lithium before it reaches systemic circulation
B) Ibuprofen directly competes with lithium for renal tubular secretion at the organic anion transporter (OAT) on the proximal tubule, reducing lithium excretion and raising plasma concentrations
C) Ibuprofen inhibits renal prostaglandin synthesis via COX (cyclooxygenase) inhibition -- renal prostaglandins (particularly PGE2 (prostaglandin E2)) normally maintain afferent arteriolar tone and glomerular filtration rate (GFR) in the kidney; by reducing PGE2, ibuprofen causes afferent arteriolar constriction, reduces GFR, and decreases glomerular filtration of lithium; lithium is freely filtered at the glomerulus and not significantly secreted or reabsorbed by tubular transporters -- therefore any reduction in GFR directly reduces lithium clearance and raises serum lithium concentrations toward toxicity
D) Ibuprofen causes prostaglandin-mediated redistribution of lithium from plasma into erythrocytes, artificially elevating the serum lithium measurement without changing total body lithium burden
E) Ibuprofen blocks sodium-lithium countertransport in red blood cell membranes, reducing intracellular lithium clearance and producing a compartmental shift that raises plasma levels
ANSWER: C
Rationale:
The ibuprofen-lithium interaction is a classic and clinically dangerous drug-drug interaction that is entirely pharmacodynamically and pharmacokinetically explicable from first principles. Lithium is a monovalent cation that is handled by the kidney similarly to sodium -- it is freely filtered at the glomerulus (not protein-bound) and undergoes partial reabsorption in the proximal tubule (approximately 70-80%) via the same sodium reabsorption mechanisms, with the remainder excreted in the urine. Crucially, lithium clearance is almost entirely dependent on glomerular filtration rate and the degree of proximal tubular sodium/lithium reabsorption -- there is essentially no significant active tubular secretion of lithium by OAT transporters. NSAIDs including ibuprofen inhibit renal prostaglandin synthesis by blocking COX-1 and COX-2 in the kidney. Renal prostaglandins (PGE2 and PGI2 (prostacyclin)) play an essential role in maintaining afferent arteriolar vasodilation and GFR -- particularly under conditions of relative volume depletion, stress, or reduced effective circulating volume. When renal prostaglandins are inhibited by NSAIDs, afferent arteriolar tone increases and GFR falls. In this patient, one week of ibuprofen reduced GFR sufficiently to reduce lithium filtration, causing lithium retention and accumulation. The lithium level rose from 0.8 to 1.9 mmol/L -- above the toxicity threshold of approximately 1.5 mmol/L -- producing the classic features of lithium toxicity (tremor, ataxia, nausea, confusion). This interaction is particularly hazardous because patients on lithium are often not warned about OTC (over-the-counter) NSAID use.
Option A: Option A is incorrect -- lithium is not hepatically metabolized; it has no CYP2D6 metabolism and no first-pass extraction; it is renally cleared unchanged.
Option B: Option B is incorrect -- lithium clearance is predominantly filtration-dependent, not secretion-dependent; OAT-mediated tubular secretion is not a significant pathway for lithium.
Option D: Option D is incorrect -- ibuprofen does not cause redistribution of lithium into erythrocytes; the elevated serum lithium reflects true systemic accumulation.
Option E: Option E is incorrect -- sodium-lithium countertransport is a research tool for measuring erythrocyte membrane transport; it is not a clinically significant pathway for systemic lithium clearance and ibuprofen does not block it.
3. A 49-year-old man with recurrent ventricular tachycardia refractory to metoprolol and flecainide is started on amiodarone. His cardiologist warns him that it may take several months to see the full antiarrhythmic effect and that if he develops side effects, they may persist for months after the drug is stopped. Which unique pharmacokinetic property of amiodarone explains both the delayed onset and the prolonged offset of its effects?
A) Amiodarone's unique property is its extremely high lipophilicity (log P approximately 7.6) combined with an exceptionally long half-life of 40-55 days -- arising from its massive volume of distribution (approximately 60 L/kg) as it distributes extensively into adipose tissue, liver, lung, and thyroid; loading doses are required to achieve therapeutic tissue concentrations quickly; when stopped, amiodarone slowly releases from tissue depots back into the circulation, maintaining pharmacologically active concentrations and both therapeutic and toxic effects for weeks to months after the last dose; this pharmacokinetic profile means drug-drug interactions with amiodarone (warfarin, digoxin, statins) persist long after the drug is stopped
B) Amiodarone's unique property is its biased agonism at cardiac beta-adrenergic receptors -- it acts as a partial agonist at baseline and switches to full antagonism during tachycardia, providing rate-adaptive antiarrhythmic coverage with slow receptor adaptation kinetics explaining the delayed onset
C) Amiodarone's unique property is irreversible covalent binding to all four ion channel types it blocks -- new channel protein synthesis is required to restore normal ion channel function after drug discontinuation, explaining why effects persist for months after stopping
D) Amiodarone's unique property is selective expression of its antiarrhythmic targets exclusively in diseased cardiac tissue -- its channels are only accessible in fibrillating or tachycardic tissue, requiring weeks of arrhythmia episodes before sufficient target engagement produces therapeutic effect
E) Amiodarone's unique property is constitutive activation of the aryl hydrocarbon receptor (AhR (aryl hydrocarbon receptor)), which drives chronic upregulation of cardiac sodium channels over weeks, producing the delayed antiarrhythmic effect through a transcriptional mechanism rather than direct channel blockade
ANSWER: A
Rationale:
Amiodarone's pharmacokinetic profile is among the most unusual of any drug in clinical use and is directly responsible for both its clinical utility and its complex toxicity management. The key parameters: log P approximately 7.6 (extremely lipophilic), volume of distribution approximately 60 L/kg (one of the largest Vd values of any drug -- meaning approximately 99% of total body amiodarone is in tissues at steady state, with only 1% in plasma), elimination half-life 40-55 days (range 26-107 days in different studies), and predominantly hepatic metabolism to the active metabolite desethylamiodarone (DEA (desethylamiodarone)), which has a similar or longer half-life. These parameters interact: the enormous Vd means that even after a large loading dose, plasma concentrations may not reflect tissue concentrations for weeks as the drug equilibrates; oral loading protocols (typically 200 mg three times daily for 1-4 weeks, then maintenance) are designed to rapidly saturate tissue compartments to achieve therapeutic concentrations faster than would occur with maintenance dosing alone. When amiodarone is stopped, the slow release from tissue depots back into the circulation sustains pharmacologically active concentrations and both antiarrhythmic effect and toxicity risk for months. Clinically important consequences: the warfarin interaction persists for weeks to months after stopping amiodarone (requiring INR monitoring and warfarin dose reduction long after discontinuation); thyroid dysfunction (both hypo- and hyperthyroidism) may appear or worsen after stopping; and pulmonary toxicity can progress even after discontinuation.
Option B: Option B is incorrect -- amiodarone is a non-competitive beta-adrenergic blocker, not a biased agonist; receptor adaptation kinetics are not the basis for its delayed onset.
Option C: Option C is incorrect -- amiodarone binds ion channels reversibly, not covalently; new channel synthesis is not required for recovery.
Option D: Option D is incorrect -- amiodarone's channels are not selectively expressed in diseased tissue; it blocks sodium, potassium, and calcium channels in all cardiac tissue.
Option E: Option E is incorrect -- while amiodarone does interact with the aryl hydrocarbon receptor pathway (contributing to some of its toxicities), this is not the established mechanism of its antiarrhythmic effect or its delayed onset/offset kinetics.
4. A 71-year-old man with a 30-year history of epilepsy well-controlled on phenytoin 300 mg daily (stable level 14 mg/L) develops a serious fungal infection and is started on voriconazole. One week later he presents with nystagmus, ataxia, and diplopia. His phenytoin level is 28 mg/L. Which of the following best explains this interaction and why the concentration rise is so disproportionately large?
A) Voriconazole is a strong inducer of CYP2C9 and CYP3A4, increasing the rate of phenytoin hydroxylation and producing a paradoxical toxic accumulation through an autoinduction mechanism
B) Voriconazole is a potent inhibitor of CYP2C9 and CYP3A4 -- the enzymes primarily responsible for phenytoin's hepatic hydroxylation to 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH (5-(para-hydroxyphenyl)-5-phenylhydantoin)); at phenytoin's therapeutic concentrations the hydroxylation pathway is already operating near saturation (Michaelis-Menten kinetics); even modest CYP2C9 inhibition by voriconazole further reduces an already-saturated elimination pathway, producing a disproportionately large rise in steady-state phenytoin concentration -- a doubling of plasma level from 14 to 28 mg/L from what might appear to be a moderate inhibitory interaction; phenytoin neurotoxicity (nystagmus, ataxia, diplopia) occurs at levels above approximately 20 mg/L
C) Voriconazole displaces phenytoin from plasma protein binding sites, rapidly increasing the free (unbound) fraction of phenytoin without changing total phenytoin concentration -- the reported level of 28 mg/L reflects total phenytoin and understates the true increase in free phenytoin, which is the pharmacologically active fraction
D) Voriconazole directly inhibits the renal tubular secretion of phenytoin at the organic anion transporter (OAT), reducing phenytoin elimination and raising plasma concentrations independently of hepatic metabolism
E) The phenytoin level rise reflects a pharmacodynamic rather than pharmacokinetic interaction -- voriconazole allosterically enhances phenytoin's binding affinity for voltage-gated sodium channels in cerebellar neurons, producing sodium channel neurotoxicity at plasma concentrations that would otherwise be non-toxic
ANSWER: B
Rationale:
This case demonstrates the dangerous intersection of two pharmacological principles: CYP enzyme inhibition and phenytoin's saturable (Michaelis-Menten) elimination kinetics. Phenytoin is metabolized primarily by CYP2C9 (approximately 90%) and secondarily by CYP2C19 to HPPH, the primary inactive hydroxylated metabolite. At therapeutic plasma concentrations (10-20 mg/L), phenytoin's concentration already approaches the Km (Michaelis constant -- the concentration at which the enzyme operates at half-maximal velocity) of CYP2C9 -- meaning the metabolizing enzyme is operating near saturation. Voriconazole is one of the most potent CYP2C9 and CYP3A4 inhibitors in clinical use (Ki values in the low nanomolar range). When voriconazole reduces CYP2C9 activity in a patient whose phenytoin hydroxylation is already near saturation, the result is dramatically amplified compared to what would occur at a lower phenytoin concentration: because the elimination pathway was already nearly saturated, even a modest additional reduction in Vmax (maximum metabolic velocity) produces a large reduction in the already-limited metabolic rate, causing rapid phenytoin accumulation. This is why the level doubled from 14 to 28 mg/L -- well above the toxicity threshold of approximately 20 mg/L -- producing classic phenytoin neurotoxicity (nystagmus, ataxia, diplopia, and at higher levels seizures paradoxically). Management requires phenytoin dose reduction (typically 25-50%), more frequent level monitoring during antifungal therapy, and awareness that the interaction resolves slowly after voriconazole is stopped (as CYP2C9 activity recovers).
Option A: Option A is incorrect -- voriconazole is a potent CYP inhibitor, not an inducer; autoinduction is a feature of carbamazepine and some other anticonvulsants, not voriconazole.
Option C: Option C is incorrect -- voriconazole does not significantly displace phenytoin from plasma proteins; the level of 28 mg/L represents a genuine increase in total (and free) phenytoin from reduced metabolism.
Option D: Option D is incorrect -- phenytoin clearance is predominantly hepatic (>95%); renal tubular secretion via OAT is not a significant elimination pathway for phenytoin.
Option E: Option E is incorrect -- voriconazole has no established pharmacodynamic interaction with voltage-gated sodium channels; the interaction is purely pharmacokinetic through CYP inhibition.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.